Hypoxia-induced mediators and neurologic disease

ALS= : amyotrophic lateral sclerosis; AMPA= : α-amino-3-hydroxy-5-methyl-4-isoxazole propionate; ATP= : adenosine triphosphate; CBP= : CREB-binding protein; COX= : cytochrome c oxidase; CREB= : cAMP-response-element-binding protein; EPO= : erythropoietin; EPOR= : EPO receptor; FIH= : factor inhibiting HIF; GLUT-1= : glucose transporter-1; HIF= : hypoxia-induced factor; HRE= : hypoxia-regulated element; IDH= : isocitrate dehydrogenase; NADPH= : nicotine-adenine nucleotide phosphate; NFκB= : nuclear factor kappa B; NOS= : nitric oxide synthase; NP= : neuropilin; PHD= : prolyl hydroxylase domain enzyme; PI3K/Akt= : phosphatidylinositol 3′kinase-Akt; POEMS= : polyneuropathy, organomegaly, endocrinopathy, M-protein, and skin changes; ROS= : reactive oxygen species; Ub= : ubiquitin; VEGF= : vascular endothelial growth factor; VEGFR= : VEGF receptor; VHL= : von Hippel–Lindau. Oxygen is the final electron acceptor in the aerobic metabolism of glucose that generates adenosine triphosphate (ATP), the source of energy for most active cellular processes. Cells have a rapid and efficient molecular response system that senses hypoxia and triggers an evolutionarily conserved pathway mediated by hypoxia-induced factor (HIF). This transcriptional regulator promotes induction of several adaptive genes that facilitate oxygen supply and support anaerobic ATP production. These genes include those encoding for glucose transporter-1 (GLUT-1), glycolytic enzymes, vascular endothelial growth factor (VEGF), and erythropoietin (EPO). During normoxia, the product of the von Hippel–Lindau (VHL) tumor suppressor gene binds to HIF and triggers its ubiquitin-mediated proteolysis. Whereas the hypoxia response has a critical adaptive role in normal cell functioning, its multiple effectors have also been implicated either in the pathogenesis or as neuroprotective factors in several neurologic disorders, including hemangioblastoma, malignant glioma, and cerebral ischemia. Both the VEGF and EPO signaling pathways are potential therapeutic targets in these and other conditions. There are several excellent reviews on all these topics.1–15 ### Hypoxia-inducible factor and oxygen sensing. HIFs are transcription factors that bind to canonical DNA sequences called hypoxia-regulated elements. These factors activate the expression of many genes encoding proteins that regulate cell metabolism, angiogenesis, vascular tone, erythropoiesis, and other functions.1–3 HIF is a heterodimeric DNA-binding complex composed of one hypoxia-inducible HIFα-subunit (HIF1α or HIF2α) and a constitutive non-oxygen-responsive subunit HIF1β.1–3 The HIF pathway is regulated by oxygen-dependent posttranslational hydroxylation of HIFα, which results in its rapid inactivation and degradation during normoxia (figure 1). HIFα subunits are substrates of a family of oxygen-dependent enzymes, including prolyl hydroxylase domain enzymes (PHDs) and aspargyl hydroxylase (factor inhibiting HIF, FIH). These enzymes act as oxygen sensors and catalyze the hydroxylation of HIFα at specific residues during normoxic conditions.1–4 These hydroxylases utilize molecular oxygen and require ferrous …

[1]  J. Bartek,et al.  Autocrine regulation of glioblastoma cell-cycle progression, viability and radioresistance through the VEGF-VEGFR2 (KDR) interplay , 2008, Cell cycle.

[2]  M. Fernando,et al.  Expression of Vascular Endothelial Growth Factor and Its Receptors in the Central Nervous System in Amyotrophic Lateral Sclerosis , 2006, Journal of neuropathology and experimental neurology.

[3]  Santosh Kesari,et al.  Malignant gliomas in adults. , 2008, The New England journal of medicine.

[4]  L. Defebvre,et al.  CSF profiles of angiogenic and inflammatory factors depend on the respiratory status of ALS patients , 2009, Amyotrophic lateral sclerosis : official publication of the World Federation of Neurology Research Group on Motor Neuron Diseases.

[5]  F. Ducray,et al.  IDH1 and IDH2 mutations in gliomas. , 2009, The New England journal of medicine.

[6]  H. Ehrenreich,et al.  A novel role for an established player: anemia drug erythropoietin for the treatment of cerebral hypoxia/ischemia. , 2004, Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis.

[7]  W. Kaelin The von Hippel–Lindau tumour suppressor protein: O2 sensing and cancer , 2008, Nature Reviews Cancer.

[8]  H. Brismar,et al.  Erythropoietin modulation of astrocyte water permeability as a component of neuroprotection , 2009, Proceedings of the National Academy of Sciences.

[9]  C. Taylor Mitochondria and cellular oxygen sensing in the HIF pathway. , 2008, The Biochemical journal.

[10]  Ling Wei,et al.  Therapeutic strategy of erythropoietin in neurological disorders. , 2008, CNS & neurological disorders drug targets.

[11]  R. D'Hooge,et al.  Novel Role for Vascular Endothelial Growth Factor (VEGF) Receptor-1 and Its Ligand VEGF-B in Motor Neuron Degeneration , 2008, The Journal of Neuroscience.

[12]  J. Gidday Cerebral preconditioning and ischaemic tolerance , 2006, Nature Reviews Neuroscience.

[13]  U. Dirnagl,et al.  Preconditioning and tolerance against cerebral ischaemia: from experimental strategies to clinical use , 2009, The Lancet Neurology.

[14]  D. Geschwind,et al.  Small Molecule Activation of Adaptive Gene Expression , 2008, Annals of the New York Academy of Sciences.

[15]  W. Kaelin,et al.  Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathway. , 2008, Molecular cell.

[16]  E. Mackenzie,et al.  Normobaric Hypoxia Induces Tolerance to Focal Permanent Cerebral Ischemia in Association with an Increased Expression of Hypoxia-Inducible Factor-1 and its Target Genes, Erythropoietin and VEGF, in the Adult Mouse Brain , 2002, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[17]  P. Wen,et al.  Novel anti-angiogenic therapies for malignant gliomas , 2008, The Lancet Neurology.

[18]  G. Pignataro,et al.  Post‐ischemic brain damage: effect of ischemic preconditioning and postconditioning and identification of potential candidates for stroke therapy , 2009, The FEBS journal.

[19]  J. Chávez,et al.  Mitochondria and Hypoxia‐induced Gene Expression Mediated by Hypoxia‐inducible Factors , 2008, Annals of the New York Academy of Sciences.

[20]  A. Zepeda,et al.  Vascular Endothelial Growth Factor Prevents Paralysis and Motoneuron Death in a Rat Model of Excitotoxic Spinal Cord Neurodegeneration , 2007, Journal of neuropathology and experimental neurology.

[21]  Ulrich Dirnagl,et al.  Ischemic tolerance and endogenous neuroprotection , 2003, Trends in Neurosciences.

[22]  Frank M. Sacks,et al.  IDH 1 and IDH 2 Mutations in Gliomas , 2009 .

[23]  A. Cerami,et al.  Emerging biological roles for erythropoietin in the nervous system , 2005, Nature Reviews Neuroscience.

[24]  Y. Itoyama,et al.  Development of a high-throughput microarray-based resequencing system for neurological disorders and its application to molecular genetics of amyotrophic lateral sclerosis. , 2008, Archives of neurology.

[25]  Xiaowen Zhang,et al.  Mutant copper‐zinc superoxide dismutase associated with amyotrophic lateral sclerosis binds to adenine/uridine‐rich stability elements in the vascular endothelial growth factor 3′‐untranslated region , 2009, Journal of neurochemistry.

[26]  Myriam Bernaudin,et al.  Hypoxic preconditioning protects against ischemic brain injury , 2011, NeuroRX.

[27]  C. Thompson,et al.  Metabolic enzymes as oncogenes or tumor suppressors. , 2009, The New England journal of medicine.

[28]  W. Robberecht,et al.  VEGF protects motor neurons against excitotoxicity by upregulation of GluR2 , 2010, Neurobiology of Aging.

[29]  A. Gregory Sorensen,et al.  Angiogenesis in brain tumours , 2007, Nature Reviews Neuroscience.

[30]  H. Ehrenreich,et al.  Therapeutic potential of erythropoietin and its structural or functional variants in the nervous system , 2011, Neurotherapeutics.

[31]  K. Stevens,et al.  VEGF and osteosclerosis in POEMS syndrome , 2008, Annals of Hematology.

[32]  D. Busam,et al.  An Integrated Genomic Analysis of Human Glioblastoma Multiforme , 2008, Science.

[33]  H. H. Marti,et al.  Erythropoietin and the hypoxic brain , 2004, Journal of Experimental Biology.

[34]  M. Hussein,et al.  Central nervous system capillary haemangioblastoma: the pathologist's viewpoint , 2007, International journal of experimental pathology.

[35]  F. Groenendaal,et al.  Neuroprotective properties and mechanisms of erythropoietin in in vitro and in vivo experimental models for hypoxia/ischemia , 2008, Brain Research Reviews.

[36]  H. H. Marti,et al.  Brain protection by erythropoietin: a manifold task. , 2008, Physiology.

[37]  G. Condorelli,et al.  Vascular endothelial growth factors in cardiovascular medicine , 2008, Journal of cardiovascular medicine.

[38]  R. Johnson,et al.  Nonrenal regulation of EPO synthesis. , 2009, Kidney international.

[39]  J. LaManna,et al.  Hypoxia-inducible Factor Prolyl 4-Hydroxylase Inhibition , 2005, Journal of Biological Chemistry.

[40]  G. Olmos,et al.  Vascular endothelial growth factor protects motoneurons from serum deprivation–induced cell death through phosphatidylinositol 3-kinase-mediated p38 mitogen-activated protein kinase inhibition , 2009, Neuroscience.

[41]  M. Bernaudin,et al.  Effect of hypoxic preconditioning on brain genomic response before and following ischemia in the adult mouse: Identification of potential neuroprotective candidates for stroke , 2006, Neurobiology of Disease.

[42]  S. Sathasivam VEGF and ALS , 2008, Neuroscience Research.